Wedge Resection for Ground-glass Opacity-featured Lung Cancer (ECTOP-1020)

Launched by FUDAN UNIVERSITY · Oct 25, 2023

Keywords

ClinConnect Summary

The ECTOP-1020 clinical trial is studying a surgical procedure called wedge resection for patients with a specific type of lung cancer known as ground-glass opacity-featured lung cancer. This type of cancer usually appears as small nodules on a CT scan and is characterized by its size (less than 2 cm) and a particular measurement called the consolidation-to-tumor ratio (CTR) that falls between 0.25 and 0.5. The main goal of this study is to see how effective this surgery is for treating this type of lung cancer.

To be eligible for the trial, participants should be between 18 and 80 years old and must have a diagnosis of lung adenocarcinoma, which is a common type of lung cancer. They should have not had any previous lung cancer surgery, chemotherapy, or radiation treatment. Participants will need to have a specific type of lung nodule and be able to undergo the wedge resection surgery, which involves removing the affected part of the lung while preserving as much healthy lung tissue as possible. This trial is currently not recruiting participants, but it aims to gather important information that could help improve treatment options for lung cancer patients in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Patients who sign the informed consent form and are willing to complete the study according to the plan;
• • 2. Aged from 18 to 80 years old;
• • 3. ECOG equals 0 or 1;
• • 4. Not receiving lung cancer surgery before;
• • 5. Intraoperative or postoperative pathologic diagnosis of lung adenocarcinoma;
• • 6. Single lung nodules with ground-glass dominant or pure ground-glass on CT, or multiple lung nodules with the major lesion being the aforementioned nodules;
• • 7. The nodule has a consolidation-to-tumor ratio (CTR) between 0.25 and 0.5 (including 0.25 and 0.5), and the nodule size is less than or equal to 2 cm;
• • 8. peripheral type of nodes, namely, nodes in the outer 1/3 of the lung field.
• • 9. cT1N0M0 tumors;
• • 10. Complete tumor resection by wedge resection as assessed by the surgeon;
• • 11. Not receiving chemotherapy or radiotherapy before.
• Exclusion Criteria:
• • 1. Postoperative pathologic diagnosis of adenocarcinoma in situ or minimally invasive adenocarcinoma.
• • 2. CTR is not between 0.25-0.5 or nodule size greater than 2 cm;
• • 3. Cannot be completely resected by wedge resection;
• • 4. Invasive lung adenocarcinoma or lung malignancy other than lung adenocarcinoma diagnosed cytologically or pathologically;
• • 5. Receiving lung cancer surgery before;
• • 6. Receiving radiotherapy or chemotherapy.